Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
BackgroundEmerging evidence indicates that immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) might be more common than initially reported, and more different clinical pictures associated with ICI-DM were described.ObjectiveThe aim of our study was to identify the clinical characteristic...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1499074/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589880370135040 |
|---|---|
| author | Mei Zhan Mei Zhan Qinran Long Qinran Long Jinhan He Jinhan He Jinhan He Litao Huang Bin Wu Bin Wu Haixia Xu Li Mo Ting Xu |
| author_facet | Mei Zhan Mei Zhan Qinran Long Qinran Long Jinhan He Jinhan He Jinhan He Litao Huang Bin Wu Bin Wu Haixia Xu Li Mo Ting Xu |
| author_sort | Mei Zhan |
| collection | DOAJ |
| description | BackgroundEmerging evidence indicates that immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) might be more common than initially reported, and more different clinical pictures associated with ICI-DM were described.ObjectiveThe aim of our study was to identify the clinical characteristics and possible predictive factors of ICI-DM.MethodsWe conducted a retrospective review of patients who received immune checkpoint inhibitors (ICI) at West China Hospital, Sichuan University until June 2023. Patients were reviewed at death or on 7 May 2024. We applied logistic regression to study the associations between clinical characteristics and ICI-DM.ResultsOur study included 8,199 participants who received ICI between October 2014 and June 2023. Among them, 1,077 patients (13.14%) developed ICI-DM according to diagnostic criteria based on guidelines. By excluding patients influenced by glucocorticoids or immunosuppressants, ICI-DM was observed in 713 of 8,199 (8.70%) patients. In all patients, hypertension, hyperlipidemia, using glucocorticoids or immunosuppressants, lung cancer, and using more than one pathway of ICI were associated with a higher risk of ICI-DM. However, the risk factors for ICI-DM in patients without the influence of glucocorticoids or immunosuppressants were only hypertension, hyperlipidemia, and pancreatic lesions. In all patients and those patients without the influence of glucocorticoids and immunosuppressants, hypertension and hyperlipidemia may increase the risk for ICI-DM.ConclusionsThis large, real-world cohort demonstrates that the incidence of ICI-DM may be underestimated in previous literature. Blood glucose monitoring is needed in patients receiving ICI therapy.Clinical trial registrationhttps://www.chictr.org.cn, identifier ChiCTR2300075974. |
| format | Article |
| id | doaj-art-f8c58cb7f9ef4eb0b69ccf6f1c0c7c3f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f8c58cb7f9ef4eb0b69ccf6f1c0c7c3f2025-01-24T07:13:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.14990741499074Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factorsMei Zhan0Mei Zhan1Qinran Long2Qinran Long3Jinhan He4Jinhan He5Jinhan He6Litao Huang7Bin Wu8Bin Wu9Haixia Xu10Li Mo11Ting Xu12Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Pharmacy, Sichuan University, Chengdu, ChinaDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Pharmacy, Sichuan University, Chengdu, ChinaDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Pharmacy, Sichuan University, Chengdu, ChinaDepartment of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Pharmacy, Sichuan University, Chengdu, ChinaDepartment of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, ChinaCenter of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaBackgroundEmerging evidence indicates that immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) might be more common than initially reported, and more different clinical pictures associated with ICI-DM were described.ObjectiveThe aim of our study was to identify the clinical characteristics and possible predictive factors of ICI-DM.MethodsWe conducted a retrospective review of patients who received immune checkpoint inhibitors (ICI) at West China Hospital, Sichuan University until June 2023. Patients were reviewed at death or on 7 May 2024. We applied logistic regression to study the associations between clinical characteristics and ICI-DM.ResultsOur study included 8,199 participants who received ICI between October 2014 and June 2023. Among them, 1,077 patients (13.14%) developed ICI-DM according to diagnostic criteria based on guidelines. By excluding patients influenced by glucocorticoids or immunosuppressants, ICI-DM was observed in 713 of 8,199 (8.70%) patients. In all patients, hypertension, hyperlipidemia, using glucocorticoids or immunosuppressants, lung cancer, and using more than one pathway of ICI were associated with a higher risk of ICI-DM. However, the risk factors for ICI-DM in patients without the influence of glucocorticoids or immunosuppressants were only hypertension, hyperlipidemia, and pancreatic lesions. In all patients and those patients without the influence of glucocorticoids and immunosuppressants, hypertension and hyperlipidemia may increase the risk for ICI-DM.ConclusionsThis large, real-world cohort demonstrates that the incidence of ICI-DM may be underestimated in previous literature. Blood glucose monitoring is needed in patients receiving ICI therapy.Clinical trial registrationhttps://www.chictr.org.cn, identifier ChiCTR2300075974.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1499074/fullimmune checkpoint inhibitorsdiabetes mellitusimmune-related adverse eventscancerimmunotherapy |
| spellingShingle | Mei Zhan Mei Zhan Qinran Long Qinran Long Jinhan He Jinhan He Jinhan He Litao Huang Bin Wu Bin Wu Haixia Xu Li Mo Ting Xu Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors Frontiers in Immunology immune checkpoint inhibitors diabetes mellitus immune-related adverse events cancer immunotherapy |
| title | Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors |
| title_full | Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors |
| title_fullStr | Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors |
| title_full_unstemmed | Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors |
| title_short | Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors |
| title_sort | immune checkpoint inhibitor induced diabetes mellitus clinical characteristics and risk factors |
| topic | immune checkpoint inhibitors diabetes mellitus immune-related adverse events cancer immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1499074/full |
| work_keys_str_mv | AT meizhan immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT meizhan immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT qinranlong immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT qinranlong immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT jinhanhe immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT jinhanhe immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT jinhanhe immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT litaohuang immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT binwu immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT binwu immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT haixiaxu immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT limo immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors AT tingxu immunecheckpointinhibitorinduceddiabetesmellitusclinicalcharacteristicsandriskfactors |